EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Characterization of tirzepatide‐treated patients achieving different glycemic control levels in SURPASS‐AP‐Combo

Yuqian Bao, Lin Han, Liying Du, Linong Ji iD

Obesity · 2024

DOI: 10.1002/oby.24030 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Obesity, 2024. Verfasst von Yuqian Bao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glycated Hemoglobin, Glycemic Control, Blood Glucose. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The study objective was to characterize subgroups of Asia‐Pacific patients with type 2 diabetes who achieved different glycated hemoglobin (HbA1c) targets on tirzepatide treatment.

Methods

This was a post hoc analysis of the SURPASS AP‐Combo study. Baseline characteristics, changes in metabolic markers, and safety were compared between tirzepatide‐treated patients achieving HbA1c

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glycated HemoglobinGlycemic ControlBlood GlucoseHypoglycemic AgentsHumansMaleMiddle AgedFemaleAdultAgedBody Mass IndexTreatment OutcomeGlucagon-Like Peptide-2 ReceptorGastric Inhibitory PolypeptideTirzepatide

Substanzen

Glycated HemoglobinBlood GlucoseHypoglycemic AgentsTirzepatidehemoglobin A1c protein, humanGlucagon-Like Peptide-2 ReceptorGastric Inhibitory Polypeptide

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Eli Lilly Suzhou Pharmaceutical Co. Ltd., Shanghai, China.
  • Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.

ORCID-Profile: Linong Ji

Förderung

  • Eli Lilly and Company

Zitieren

APA

Bao, Y., Han, L., Du, L., & Ji, L. (2024). Characterization of tirzepatide‐treated patients achieving different glycemic control levels in SURPASS‐AP‐Combo. Obesity. https://doi.org/10.1002/oby.24030

Vancouver

Bao Y, Han L, Du L, Ji L. Characterization of tirzepatide‐treated patients achieving different glycemic control levels in SURPASS‐AP‐Combo. Obesity. 2024. doi:10.1002/oby.24030

BibTeX
@article{Bao2024,
  author = {Bao, Yuqian and Han, Lin and Du, Liying and Ji, Linong},
  title = {Characterization of tirzepatide‐treated patients achieving different glycemic control levels in SURPASS‐AP‐Combo},
  journal = {Obesity},
  year = {2024},
  doi = {10.1002/oby.24030}
}
Kostenlos starten →